TrialPath
Recruiting

A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

NCT07483099 · Eli Lilly and Company
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared With Mirikizumab in Adults With Moderately to Severely Active Crohn's Disease
About this study
The main purpose of this study is to see how the safety and efficacy of a farnesoid X receptor (FXR) agonist (LY4395089), given together with mirikizumab compares with mirikizumab (alone) in adults with moderately to severely active Crohn's disease (CD). This study is part of the IIBD master protocol and will last approximately 62 weeks.
Eligibility criteria
Inclusion Criteria: Participants must meet all the inclusion criteria in the IIBD master protocol, except the UC-specific criteria. In addition, they must meet the criteria below: * Participants taking glucagon-like peptide-1 (GLP-1) receptor agonists (RAs), GLP-1/glucose-dependent insulinotropic polypeptide (GIP) RAs, GLP-1/glucagon (Gcg) RAs, GLP-1/GIP/Gcg RAs, or similar medications for approved indications will be permitted to enroll provided they are on a stable dose at the time of screening Exclusion Criteria: Participants are excluded from the study if any of the exclusion criteria in the IIBD master protocol, except the UC-specific criteria apply, or if any of the following criteria apply: * Must not have a hepatic disease * Must not have a history of any other bone disease that affects bone metabolism * Must not have had any of the following within the past 180 days before screening: * acute myocardial infarction * cerebrovascular incident * hospitalization for unstable angina * hospitalization due to congestive heart failure, or * coronary revascularization * Must not have received or will need any other prohibited medications as specified in the protocol
Study design
Enrollment target: 60 participants
Allocation: randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-05-04
Estimated completion: 2028-03
Last updated: 2026-11-04
Interventions
Drug: LY4395089Drug: Mirikizumab - Intravenous (IV)Drug: Mirikizumab - Subcutaneous (SC)
Primary outcomes
  • • Percentage of Participants with Crohn's Disease who Achieve Endoscopic Response (Baseline, Up to Week 12)
Sponsor
Eli Lilly and Company · industry
Contacts & investigators
ContactThere may be multiple sites in this clinical trial. (Add "This 1-877-CTLILLY (1-877-285-4559) or · contact · clinical_inquiry_hub@lilly.com · 1-317-615-4559
InvestigatorContact Lilly at 1-877-CTLILLY (1-877-285-4559) or · study_director, Eli Lilly and Company
All locations (71)
Mayo Clinic in Arizona - ScottsdaleSuspended
Scottsdale, Arizona, United States
Biopharma Informatic, LLCNot Yet Recruiting
Los Angeles, California, United States
Om Research LLCRecruiting
Oxnard, California, United States
South Denver GastroenterologyRecruiting
Englewood, Colorado, United States
Gastro Health Research - MiamiRecruiting
Miami, Florida, United States
Ezy Medical ResearchRecruiting
Miami Lakes, Florida, United States
Atlanta Gastroenterology Associates - Peachtree DunwoodyRecruiting
Atlanta, Georgia, United States
Rush University Medical CenterNot Yet Recruiting
Chicago, Illinois, United States
Cotton O'Neil Digestive Health CenterRecruiting
Topeka, Kansas, United States
Gastroenterology Associates of Western Michigan, PLC d.b.a. West Michigan Clinical Research CenterNot Yet Recruiting
Wyoming, Michigan, United States
KAD Clinical ResearchRecruiting
St Louis, Missouri, United States
Vector Clinical TrialsRecruiting
Las Vegas, Nevada, United States
One of a Kind Clinical Research Center - KingwoodRecruiting
Kingwood, Texas, United States
Southern Star Research InstituteRecruiting
San Antonio, Texas, United States
AZ Maria MiddelaresRecruiting
Ghent, Belgium
UZ GentNot Yet Recruiting
Ghent, Belgium
UZ LeuvenRecruiting
Leuven, Belgium
AZ Delta vzwRecruiting
Roeselare, Belgium
Loema Instituto de Pesquisa ClinicaRecruiting
Campinas, Brazil
Fundação Universidade de Caxias do Sul (FUCS)Recruiting
Caxias do Sul, Brazil
Centro Digestivo de CuritibaRecruiting
Curitiba, Brazil
Centro de Pesquisa Clínica de Marília - CPCLIMRecruiting
Marília, Brazil
CPHosp Medicina, Ensino e Pesquisa (CPQuali)Recruiting
São Paulo, Brazil
CPCLINRecruiting
São Paulo, Brazil
BR Trials - Ensaios Clinicos e ConsultoriaRecruiting
São Paulo, Brazil
Clínica Hepatogastro JKRecruiting
São Paulo, Brazil
CEDOESRecruiting
Vitória, Brazil
Centre Intégré de Santé et de Services Sociaux de la Montérégie-CentreNot Yet Recruiting
Greenfield Park, Canada
Prairie Institute of Liver and Luminal Advanced Research Ltd (PILLAR)Not Yet Recruiting
Lethbridge, Canada
London Digestive Disease InstituteNot Yet Recruiting
London, Canada
Tdda Inc.Recruiting
Vaughan, Canada
The Second Xiangya Hospital of Central South UniversityRecruiting
Changsha, China
Changzhou Second People's HospitalRecruiting
Changzhou, China
The First Affiliated Hospital, Sun Yat-sen UniversityRecruiting
Guangzhou, China
The Second Affiliated hospital of Zhejiang University school of medicineRecruiting
Hangzhou, China
Huizhou Central People's HospitalRecruiting
Huizhou, China
The Second Affiliated Hospital of Soochow UniversityRecruiting
Suzhou, China
The Second Affiliated Hospital YuYing Childens Hospital of Wenzhou Medical universityRecruiting
Wenzhou, China
Zhongshan Hospital Affiliated to Xiamen UniversityRecruiting
Xiamen, China
Affiliated Hospital of Jiangsu UniversityRecruiting
Zhenjiang, China
Charité Universitaetsmedizin Berlin - Campus MitteNot Yet Recruiting
Berlin, Germany
Studienzentrum MVZ DachauSuspended
Dachau, Germany
Studiengesellschaft Mitteldeutschland GmbHRecruiting
Halle, Germany
St. Marien- und St. AnnastiftskrankenhausRecruiting
Ludwigshafen, Germany
Universitaetsklinikum UlmNot Yet Recruiting
Ulm, Germany
Geomedical Egészségügyi KözpontRecruiting
Budapest, Hungary
Semmelweis EgyetemRecruiting
Budapest, Hungary
Komarom-Esztergom Varmegyei Szent Borbala KorhazRecruiting
Tatabánya, Hungary
Assuta Ashdod Medical CenterRecruiting
Ashdod, Israel
Rambam Health Care CampusRecruiting
Haifa, Israel
Shaare Zedek Medical CenterRecruiting
Jerusalem, Israel
Hadassah Medical CenterRecruiting
Jerusalem, Israel
Rabin Medical CenterRecruiting
Petah Tikva, Israel
Sheba Medical CenterRecruiting
Ramat Gan, Israel
Yitzhak Shamir Medical CenterRecruiting
Tsrifin, Israel
Azienda Ospedaliera Universitaria CareggiRecruiting
Florence, Italy
Ospedale San RaffaeleNot Yet Recruiting
Milan, Italy
Fondazione IRCCS San Gerardo dei TintoriNot Yet Recruiting
Monza, Italy
Ospedale Sacro Cuore Don G. CalabriaNot Yet Recruiting
Negrar, Italy
Fondazione Policlinico Universitario Agostino GemelliNot Yet Recruiting
Roma, Italy
HumanitasNot Yet Recruiting
Rozzano, Italy
Gyncentrum sp. z o.o. NZOZ Holsamed - oddział LiberoRecruiting
Katowice, Poland
Centrum Medyczne OslomedRecruiting
Krakow, Poland
Medrise Sp. z o.o.Not Yet Recruiting
Lublin, Poland
Twoja Przychodnia PCMRecruiting
Poznan, Poland
ETG SiedlceRecruiting
Siedlce, Poland
Twoja Przychodnia SCMRecruiting
Szczecin, Poland
Sonomed Sp. z o. o.Recruiting
Szczecin, Poland
WSD MEDINot Yet Recruiting
Warsaw, Poland
Medical Network Spółka z o.o. WIP Warsaw IBD Point Profesor KierkuśRecruiting
Warsaw, Poland
ETG ZamośćRecruiting
Zamość, Poland